Loading...
•
Dec 31, 2024
Liquidia Q4 2024 Earnings Report
Liquidia reported its Q4 2024 financial results with continued net losses and modest revenue from promotion agreements.
Key Takeaways
Liquidia Corporation continued to report losses in Q4 2024 as it prepares for potential YUTREPIA approval. Revenue remained modest, impacted by pump availability constraints. The company strengthened its cash position through amended financing agreements.
Q4 revenue was $2,921,000, driven by the promotion agreement with Sandoz.
Q4 net loss was $38,375,000 as R&D and legal expenses continued to grow.
Cash and cash equivalents reached $176,479,000 by year-end, boosted by new financing agreements.
The company is targeting final FDA approval for YUTREPIA after May 23, 2025.
Liquidia
Liquidia
Liquidia Revenue by Segment
Liquidia Revenue by Geographic Location
Revenue by Segment
Promotion Agreement Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Liquidia expects to secure final FDA approval for YUTREPIA after May 2025 and plans to continue advancing its pipeline while managing expenses.
Positive Outlook
- Targeting final FDA approval of YUTREPIA after May 23, 2025.
- Strong cash position supported by amended financing agreement with HCRx.
- Advancement of ASCENT and L606 clinical programs.
- Ongoing robust development in sustained-release treprostinil pipeline.
- Positioned to commercialize YUTREPIA in both PAH and PH-ILD markets.
Challenges Ahead
- Revenue continues to be impacted by limited pump availability for Treprostinil Injection.
- High ongoing legal expenses due to YUTREPIA-related litigation.
- Increased R&D expenses as trials expand.
- Significant net loss expected to persist until product approval and commercialization.
- Dependence on regulatory timelines and potential litigation delays.